

June 10, 2020

Denka Company Limited

The Research Proposal for the Multiplex Molecular Diagnosis Systems Included SARS-CoV-2 was Adopted by the Subsidy Project of the Japan Agency for Medical Research and Development (AMED)

Denka Company Limited (headquarters: Chuo-ku, Tokyo; president: Manabu Yamamoto; hereinafter “Denka”) is pleased to announce that the project of development for the multiplex molecular diagnosis systems included the SARS-CoV-2 infectious disease was adopted by the subsidy project of the Japan Agency for Medical Research and Development, AMED as a Program for Technology Development of Countermeasures against Virus and Other Infectious Diseases (experimental study/modification research support).

The purpose of this research project is for the development and evaluation of usefulness of a new testing method that simultaneously detects multiple microorganisms that cause infectious diseases, including COVID-19. Denka will make an announcement immediately after all of the contracts related with the grant application has been completed.

As a part of its responsibility to society regarding measures to address the COVID-19, in addition to the research project above, Denka is developing immunochromatography testing kits and the examination of the ELISA (enzyme-linked immuno-sorbent assay) method. Denka will contribute to improving testing systems continuously, while seeking cooperation and support from the authorities, public institutions and research institutions in Japan and overseas.

About Denka: Denka is a chemical manufacturer headquartered in Chuo-ku, Tokyo. The company specializes in developing business activities on a global scale across a wide range of fields, from inorganic and organic chemicals, to electronic materials and pharmaceuticals. Founded in 1915, Denka has steadily continued to develop and manufacture products that contribute to the development of society by fully utilizing its unique concepts and technological capabilities. Upholding its corporate slogan, “Possibility of chemistry,” the company and its president, Manabu Yamamoto, are committed to contributing to the sound development of society while sincerely tackling the challenges that society is now confronting.

[For Inquiries from the Media about This Press Release]

Corporate Communications Dept. Tel : +81-3-5290-5511